Each capsule contains Imatinib Mesylate equivalent to Imatinib 100mg.
matinib Mesylate is a protein - tyrosine kinase inhibitor that inhibits the Bcr-Abl tyrosine kinase, the constitutive abnormal tyrosine kinase created by the Philadelphia Chromosome abnormality in Chronic Myeloid Leukemia (CML).
VEENAT (Imatinib Mesylate) is indicated for the treatment of patients with Philadelphia Chromosome positive Chronic Myeloid Leukemia (CML) in blast crisis, accelerated phase, or in chronic phase.
Dosage & Usage:
Therapy should be initiated under experienced medical guidance in the treatment of patient with Chronic Myeloid Leukemia (CML).
The prescribed dose should be administered orally, with a meal and a large glass of water. Doses of 400mg under chronic phase & 600mg under accelerated phase should be administered once daily or as prescribed by your doctor.
Some common side effects that may occur as a result of the usage of Veenat, include - nausea, vomiting, diarrhea, muscle cramps. If these symptoms persist or worsen, contact your doctor immediately.
Note: Veenat is a prescription drug and should be used under proper medical guidance and advice. Do not share the medicine with others, since they may be suffering from a problem that is not effectively treated by this drug.